Literature DB >> 12354783

Carriership of a defective tenascin-X gene in steroid 21-hydroxylase deficiency patients: TNXB -TNXA hybrids in apparent large-scale gene conversions.

Paul F J Koppens1, Theo Hoogenboezem, Herman J Degenhart.   

Abstract

Steroid 21-hydroxylase deficiency is caused by a defect in the CYP21A2 gene. CYP21A2, the adjacent complement C4 gene and parts of the flanking genes RP1 and TNXB constitute a tandemly duplicated arrangement in the central (class III) region of the major histocompatibility complex. The typical number of repeats of the CYP21/C4 region is two, with one repeat carrying CYP21A2 and the other carrying the highly homologous pseudogene CYP21A1P. By comparison with this standard, three categories of CYP21A2 defects have traditionally been distinguished: CYP21A2 deletions, large-scale gene conversions of CYP21A2 into a structure similar to CYP21A1P, and smaller mutations in CYP21A2 (also derived from CYP21A1P, by means of small-scale gene conversions). The genetic mechanisms suggested by these designations have originally been inferred from the layout of the haplotypes involved and were later confirmed by observation of deletions and small mutations, but not large-scale conversions, as de novo events. Apparent large-scale conversions account for the defect in 9 out of 77 chromosomes in our patient group. We here demonstrate that 4 out of these 9 'conversions' extend into the flanking TNXB gene, which encodes tenascin-X. This implies that approximately 1 in every 10 steroid 21-hydroxylase deficiency patients is a carrier of tenascin-X deficiency, which is associated with a recessive form of the Ehlers-Danlos syndrome. Currently available data on the structure of 'deletion' and 'large-scale conversion' chromosomes strongly suggests that both are the result of the same mechanism, namely unequal meiotic crossover. Since it is unlikely that the term 'large-scale gene conversion' describes a mechanism that actually occurs between the CYP21A2 and CYP21A1P genes, we propose the discontinuation of that terminology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12354783     DOI: 10.1093/hmg/11.21.2581

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  9 in total

1.  Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Gabriela P Finkielstain; Wuyan Chen; Sneha P Mehta; Frank K Fujimura; Reem M Hanna; Carol Van Ryzin; Nazli B McDonnell; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2010-10-06       Impact factor: 5.958

2.  The residue E351 is essential for the activity of human 21-hydroxylase: evidence from a naturally occurring novel point mutation compared with artificial mutants generated by single amino acid substitutions.

Authors:  Nils Krone; Felix G Riepe; Joachim Grötzinger; Carl-Joachim Partsch; Jürgen Brämswig; Wolfgang G Sippell
Journal:  J Mol Med (Berl)       Date:  2005-04-14       Impact factor: 4.599

3.  Issues with the Detection of Large Genomic Rearrangements in Molecular Diagnosis of 21-Hydroxylase Deficiency.

Authors:  Paola Concolino
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

4.  Nonclassic congenital adrenal hyperplasia.

Authors:  Selma Feldman Witchel; Ricardo Azziz
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-30

5.  Complement component 4 copy number variation and CYP21A2 genotype associations in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Wuyan Chen; Zhi Xu; Miki Nishitani; Carol Van Ryzin; Nazli B McDonnell; Deborah P Merke
Journal:  Hum Genet       Date:  2012-08-12       Impact factor: 4.132

6.  The phenotypic spectrum of contiguous deletion of CYP21A2 and tenascin XB: quadricuspid aortic valve and other midline defects.

Authors:  Wuyan Chen; Mimi S Kim; Sujata Shanbhag; Andrew Arai; Carol VanRyzin; Nazli B McDonnell; Deborah P Merke
Journal:  Am J Med Genet A       Date:  2009-12       Impact factor: 2.802

Review 7.  Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase Deficiency: A Comprehensive Focus on 233 Pathogenic Variants of CYP21A2 Gene.

Authors:  Paola Concolino; Alessandra Costella
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.074

8.  Genotype-phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: analysis of the United Kingdom Congenital adrenal Hyperplasia Adult Study Executive (CaHASE) cohort.

Authors:  Nils Krone; Ian T Rose; Debbie S Willis; James Hodson; Sarah H Wild; Emma J Doherty; Stefanie Hahner; Silvia Parajes; Roland H Stimson; Thang S Han; Paul V Carroll; Gerry S Conway; Brian R Walker; Fiona MacDonald; Richard J Ross; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2013-01-21       Impact factor: 5.958

9.  Intraspecific evolution of human RCCX copy number variation traced by haplotypes of the CYP21A2 gene.

Authors:  Zsófia Bánlaki; Julianna Anna Szabó; Ágnes Szilágyi; Attila Patócs; Zoltán Prohászka; George Füst; Márton Doleschall
Journal:  Genome Biol Evol       Date:  2013       Impact factor: 3.416

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.